MARTINSRIED and MUNICH, Germany, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced today the appointment of Pamela Keck as Vice President, Head of Investor Relations and Corporate Communications. “Pamela’s extensive investor relations experience in the biotech industry and wealth of financial expertise will be invaluabl
Milestone payment is related to the establishment of 2seventy bio’s strategic partnership with JW TherapeuticsPayment provides further validation of Medigene’s end-to-end platform MARTINSRIED, Germany and MUNICH, Germany, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Martinsried -- Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focused on the development of differentiated, best-in-class T Cell Receptor engineered T cell (TCR-T) therapies, today announced that it has received a
We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits...